Unmet Needs in Patient Care for Metastatic Colorectal Cancer

Trastuzumab/pertuzumab elicited similar efficacy and fewer high-grade AEs vs cetuximab/irinotecan in RAS/BRAF wild-type, HER2–positive metastatic CRC.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Updated efficacy findings from the phase 3 CheckMate-8HW trial also showed fewer grade 3/4 adverse events with nivolumab/ipilimumab vs chemotherapy.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.